Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Anastrozole
Drug ID BADD_D00142
Description Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to [letrozole], used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer.[L8863] Anastrozole is also related to [exemestane], a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated adverse effects such as weight gain and acne.[A186865] Aromatase inhibitors, including anastrozole, have become endocrine drugs of choice in the treatment of postmenopausal breast cancer due to a more favourable efficacy and adverse effect profile as compared to earlier estrogen receptor modulators such as [tamoxifen].[A186877,A186955] Anastrozole was first approved for use in the United States in 1995.[L8863]
Indications and Usage Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women.[L8863] It may also be used in the treatment of advanced breast cancer in postmenopausal women who experience disease progression despite treatment with [tamoxifen].[L8866,L8863]
Marketing Status approved; investigational
ATC Code L02BG03
DrugBank ID DB01217
KEGG ID D00960
MeSH ID D000077384
PubChem ID 2187
TTD Drug ID D0W0BF
NDC Product Code 38779-2555; 58623-0041; 73377-120; 65841-743; 70518-2420; 0310-0201; 51927-4435; 68071-1543; 68071-2791; 46014-1009; 69988-0013; 71052-248; 63187-080; 63629-5269; 70518-2484; 59651-236; 63850-0010; 71335-1879; 0904-6195; 46014-1160; 61200-104; 68554-0026; 16571-421; 0093-7536; 51991-620; 68382-209; 63850-6527; 50090-2453; 50090-5812; 68001-155; 65072-0702; 65129-1119; 16729-035; 42291-016; 50268-075; 60687-112; 68071-5203; 62991-3176; 43063-383; 62559-670; 72789-008; 55111-814; 62135-490; 72189-415; 53104-7627; 65096-0117; 42291-085; 76420-004; 51552-1568; 60440-2921; 62157-077; 62756-428; 82393-201
UNII 2Z07MYW1AZ
Synonyms Anastrozole | 2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile) | Anastrazole | Arimidex | ICI D1033 | ZD-1033 | ZD 1033 | Zeneca ZD 1033 | ZD1033
Chemical Information
Molecular Formula C17H19N5
CAS Registry Number 120511-73-1
SMILES CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lipid metabolism disorder14.08.04.003--Not Available
Ischaemic stroke24.04.06.010; 17.08.01.0180.001509%Not Available
Metastatic neoplasm16.16.01.0070.000397%Not Available
Neoplasm progression16.16.02.0050.000477%Not Available
Venous thrombosis limb24.01.02.0090.000238%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Ill-defined disorder08.01.03.049--Not Available
Inner ear disorder04.04.02.0020.000477%Not Available
Bone lesion15.02.04.0160.000318%Not Available
Disease progression08.01.03.0380.003448%
Disease recurrence08.01.03.0500.002066%Not Available
Drug intolerance08.06.01.0130.003337%Not Available
Neoplasm recurrence16.16.02.0040.000159%Not Available
Obstructive airways disorder22.03.01.011--Not Available
Pulmonary toxicity22.01.02.007; 12.03.01.0130.000238%Not Available
Hepatic lesion09.01.08.0050.000159%Not Available
Hepatobiliary disease09.01.08.003--Not Available
Metastasis16.22.01.0010.000556%Not Available
Nasal disorder22.04.03.0040.000238%Not Available
Renal impairment20.01.03.0100.000715%Not Available
Complex regional pain syndrome17.02.07.010; 12.01.12.0040.000159%Not Available
Osteonecrosis of jaw15.02.04.010; 24.04.05.0050.000953%
Tendon pain15.07.01.0090.000667%Not Available
Liver injury12.01.17.012; 09.01.07.0220.000159%Not Available
Organising pneumonia22.01.02.0080.001907%Not Available
Adverse reaction08.06.01.0180.000318%Not Available
Oestrogenic effect05.05.04.004; 08.06.01.043--Not Available
Focal segmental glomerulosclerosis20.05.01.0030.000238%Not Available
Skin mass23.07.04.0140.000159%Not Available
Androgenetic alopecia05.05.04.001; 23.02.02.0020.000540%Not Available
The 14th Page    First    Pre   14 15 16    Next   Last    Total 16 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene